Apimeds Pharmaceuticals sets July 24 reverse stock split

Apimeds Pharmaceuticals US, Inc. will implement a 1-for-10 reverse stock split of its issued and outstanding common stock.

Rhea-AI Filing Summary

Apimeds Pharmaceuticals US, Inc. will implement a 1-for-10 reverse stock split of its issued and outstanding common stock. The company plans to file a charter amendment with the Delaware Secretary of State on or about July 23, 2026, and has set the reverse split to become effective as of 12:01 a.m. Eastern Time on July 24, 2026.

Following effectiveness, every ten shares of common stock will automatically be combined into one share, and the stock is expected to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS at the open of trading on July 24, 2026. The new CUSIP for the common stock will be 03771D201. Stockholders previously approved the reverse split by majority written consent on December 1, 2025, after which an information statement was mailed and the required waiting period has elapsed.

Filing Explained

Existing shares are scheduled to consolidate one-for-ten on July 24, 2026; the change is announced but not yet effective.

The July 13, 2026 Form 8-K, which reports specified material events, says stockholders approved a one-for-ten reverse stock split, but it has not yet become effective.

Once effective, every ten issued and outstanding common shares will automatically become one share, reducing the share count and proportionally raising the per-share price; the split itself does not change company value.

The company did not file the required Charter Amendment on the previously expected March 26, 2026 effective date and now expects to file it on or about July 23, 2026, with effectiveness set for July 24, 2026.

The filing says the company will announce effectiveness in a subsequent 8-K once the July 24, 2026 Effective Date occurs.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Reverse stock split ratio: 1-for-10 Effective time of reverse split: 12:01 a.m. Eastern Time on July 24, 2026 Planned filing date of charter amendment: On or about July 23, 2026 +3 more

6 metrics

Reverse stock split ratio 1-for-10 Every ten shares of issued and outstanding common stock will be combined into one share

Effective time of reverse split 12:01 a.m. Eastern Time on July 24, 2026 Time at which the reverse stock split will become effective

Planned filing date of charter amendment On or about July 23, 2026 Expected date to file Charter Amendment with Delaware Secretary of State

New CUSIP for common stock 03771D201 CUSIP number for Apimeds Pharmaceuticals’ common stock following the reverse stock split

Stockholder approval date December 1, 2025 Date stockholders holding a majority of voting power approved the reverse stock split by written consent

Information Statement mailing date March 5, 2026 Date the Information Statement regarding the reverse stock split was first mailed to stockholders

Key Terms

Reverse Stock Split, Written Consent, Information Statement, Emerging growth company, +1 more

5 terms

Reverse Stock Split financial

"to effect a reverse stock split of its issued and outstanding shares of common stock"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

Written Consent regulatory

"by written consent (the “Written Consent”), to effect a reverse stock split"

A written consent is a formal, signed document in which shareholders or directors approve a corporate action without holding a live meeting, similar to signing a petition instead of gathering in person. It matters to investors because it can speed decisions, create a clear legal record of approval, and affect control or governance outcomes — for example enabling changes that would otherwise require a vote at a meeting.

Information Statement regulatory

"filed and mailed an information statement (the “Information Statement”) to its stockholders"

An information statement is a formal document companies distribute to investors and the public to explain important facts about a corporate action, transaction, or situation — for example changes in management, business plans, or financial events. It’s like a clear, written notice that lays out what happened and why it matters, helping investors judge risk and make decisions without being asked to vote. Reliable, timely information can affect share prices and investor trust.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Charter Amendment regulatory

"to amend the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”)"

A charter amendment is a formal change to a corporation’s founding document — its legal rulebook that sets basic structure, powers and shareholder rights. Investors care because amending the charter can alter voting rules, share classes, dividend policies or takeover protections, which can change how value and control are distributed; think of it as revising a building’s blueprint that affects who owns which rooms and who can remodel next.

FAQ

What reverse stock split did Apimeds Pharmaceuticals (APUS) approve?

Apimeds Pharmaceuticals approved a 1-for-10 reverse stock split of its common stock. Every ten existing shares will be automatically combined and changed into one share of issued and outstanding common stock upon effectiveness.

When does the Apimeds Pharmaceuticals (APUS) reverse stock split become effective?

The reverse stock split becomes effective at 12:01 a.m. Eastern Time on July 24, 2026. The company expects to file the related charter amendment on or about July 23, 2026, with split-adjusted trading beginning July 24, 2026.

When will Apimeds Pharmaceuticals (APUS) start trading on a split-adjusted basis?

Apimeds Pharmaceuticals expects its common stock to begin trading on a split-adjusted basis on the NYSE American at the open of trading on July 24, 2026, following effectiveness of the 1-for-10 reverse stock split.

What is the new CUSIP for Apimeds Pharmaceuticals (APUS) after the reverse split?

After the reverse stock split, the common stock of Apimeds Pharmaceuticals will have a new CUSIP of 03771D201. The shares will continue to trade on the NYSE American under the symbol APUS on a split-adjusted basis.

How and when did Apimeds Pharmaceuticals (APUS) shareholders approve the reverse split?

Stockholders holding a majority of the voting power approved the 1-for-10 reverse stock split by written consent on December 1, 2025. An information statement dated February 26, 2026 was mailed to stockholders on March 5, 2026.

Why did Apimeds Pharmaceuticals (APUS) change the original effective date of the reverse split?

The company had previously anticipated a March 26, 2026 effective date but did not file the charter amendment then. It now expects effectiveness at 12:01 a.m. Eastern Time on July 24, 2026 after the waiting period has passed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 04:31 PM Accepted by SEC EDGAR 07/13/2026 - 04:30 PM Learn about SEC filing dates

false 0001894525 0001894525 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 13, 2026

Apimeds Pharmaceuticals US, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42545		85-1099700
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

100 Matawan Rd, Suite 325 Matawan, New Jersey		07747
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (848) 201-5010

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		APUS		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On December 1, 2025, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), obtained approval of its stockholders holding a majority of the voting power of the Company’s outstanding capital stock, by written consent (the “Written Consent”), to effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-ten (1-for-10) (the “Reverse Stock Split”) and to amend the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) accordingly.

In connection with the Written Consent, the Company filed and mailed an information statement (the “Information Statement”) to its stockholders pursuant to Rule 14c-2 under the Securities Exchange Act of 1943, as amended. The Reverse Stock Split will not become effective until at least 20 calendar days after the mailing of the definitive Information Statement (the “Waiting Period”).

As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2026, the Company had expected to file the Charter Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split on or about March 25, 2026, with the Reverse Stock Split becoming effective on March 26, 2026. The Company did not file the Charter Amendment on that date. The Waiting Period has now passed, and the Company expects to file the Charter Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split on or about July 23, 2026.

The Company has determined that the Reverse Stock Split will become effective as of 12:01 a.m. Eastern Time on July 24, 2026 (the “Effective Date”), in lieu of the previously announced Effective Date of March 26, 2026. The Company expects that its common stock will begin trading on a split-adjusted basis on the NYSE American LLC under the symbol “APUS”, at the open of trading on July 24, 2026. The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 03771D201.

Upon effectiveness of the Reverse Stock Split, every ten (10) shares of the Company’s issued and outstanding common stock will automatically be combined and changed into one (1) share of the Company’s issued and outstanding common stock.

The information set forth in this Item 8.01 does not purport to be complete and is qualified in its entirety by reference to the disclosure under the heading “The Reverse Stock Split” in the Information Statement, which was dated February 26, 2026, and first mailed to stockholders on March 5, 2026, and is incorporated herein by reference. 

The Company will announce the effectiveness of the Reverse Stock Split in a subsequent Current Report on Form 8-K once the Effective Date occurs.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Apimeds Pharmaceuticals US, Inc.
Date: July 13, 2026	By:	/s/ Dr. Vin Menon
	Name:	Dr. Vin Menon
	Title:	Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB